Gilead acquires XinThera to strengthen pipeline in oncology and inflammation
May 10, 2023Sales and Marketing Gilead, Oncology, XinThera, inflammation, oncology
Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech company based in San Diego, …
Eyenovia announces FDA approval of first ophthalmic spray for mydriasis
May 10, 2023Research and Development Eyenovia, FDA, Opthalmology, mydriasis, ophthalmology
Ophthalmic technology company Eyenovia has announced that the US Food and Drug Administration (FDA) has approved Mydcombi (tropicamide and phenylephrine …
Sobi acquires CTI BioPharma Corporation for $1.7bn
May 10, 2023Medical Communications CTI, acquisition, sobi
Swedish Orphan Biovitrum, aka Sobi, has announced that it had entered into a ‘plan of merger’ with CTI BioPharma Corp …
Thermo Fisher and Pfizer collaborate on NGS-based cancer tests
May 10, 2023Medical Communications Cancer, NGS, Oncology, Pfizer, Thermo Fisher Scientifitic, oncology
Scientific equipment provider Thermo Fisher and US pharmaceutical firm Pfizer have announced a collaboration to advance next-generation sequencing (NGS)-based cancer …
FlyPharma Europe, Vienna: the early bird deal for FlyPharma Vienna closes on 24 May
May 9, 2023Business Services, Conferences Conference, flypharma
Act now! The early bird deal for FlyPharma Vienna closes on 24 May. Contact Angela Heath, conference director, email angela@samedanltd.com for …
Pharmacists in England given wider prescribing powers to relieve GP pressure
May 9, 2023Medical Communications GP, NHS England, pharmacists
NHS England had announced that pharmacists in England will be given wider prescribing powers to relieve pressure put on GPs. …
AstraZeneca’s Farxiga approved to reduce risk of cardiovascular death
May 9, 2023Medical Communications AstraZeneca, Cardiology, FDA, cvd, farxiga, heart failure
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Farxiga to reduce the risk of cardiovascular …
CureVac and GSK begin phase 1 trial for mRNA flu vaccine candidates
May 9, 2023Medical Communications CureVac, GSK, Virology, clinical trial, mrna, vaccines
CureVac and GSK have announced that the first patient in the phase 1 section of their combined phase 1/2 trial …
Boehringer Ingelheim and Ginkgo Bioworks collaborate over $406m undruggable targets deal
May 9, 2023Research and Development Boehringer Ingelheim, Rare Diseases, cell programming, ginkgo bioworks, undruggable targets
German pharmaceutical company Boehringer Ingelheim (BI) and cell programming and biosecurity platform builder Ginkgo Bioworks have announced a partnership to …
Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease
May 5, 2023Research and Development Alzheimer's disease, Eli Lilly, Neurology, clinical trial, new drug
Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s ability to slow cognitive and …
FDA accepts sNDA for Optinose’s XHANCE
May 5, 2023Medical Communications Ear Nose & throat, FDA, Nasal Spray, optinose, sNDA
Optinose has announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for …
Nanobiotix enters final contract negotiations with major pharma company
May 5, 2023Medical Communications FDA, Oncology, nanobiotix, oncology
French late-stage clinical biotechnology company Nanobiotix has announced that it has entered into final contract negotiations with a major pharmaceutical …
Cognixion receives FDA Breakthrough Device Designation for assisted communication device
May 5, 2023Medical Communications Cognixion, FDA, Neurology, brain computer interface, breakthrough device designation, neuroscience
Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and …
PureTech Health’s Founded Entity Akili announces positive data from adult ADHD trial
May 4, 2023Medical Communications ADHD, Akili, Neurology, PureTech Health, clinical trials
Clinical-stage biotherapeutics company PureTech Health has reported that its Founded Entity Akili, a digital medicine company, has announced positive topline …
FDA approves world’s first RSV vaccine
May 4, 2023Medical Communications FDA, RSV, Vaccine, Virology
The US Food and Drug Administration (FDA) has announced that it has approved the world’s first respiratory syncytial virus (RSV) …
Vicore announces initiation of proof-of-concept study for endothelial dysfunction treatments
May 4, 2023Research and Development Cardiology, Vicore Pharma, clinical trials, endothelial dysfunction, organ damage
Vicore Pharma Holding AB has announced that it has dosed the first patient with C21 in its randomised, double-blind, placebo-controlled, …
NICE recommends Otsuka’s Lupkynis (voclosporin) in combination treatment for active lupus nephritis
May 4, 2023Medical Communications MHRA, NICE, Nephrology, Otsuka Pharmaceuticals, lupus nephritis
Otsuka Pharmaceuticals has announced that the National Institutes for Health and Care Excellence (NICE) has recommended Lupkynis (voclosporin) in combination …
Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment
May 3, 2023Sales and Marketing License Agreement, Pompe disease, Rare Diseases, Sanofi, maze therapeutics, treatment
Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement for Maze’s gluogen synthase 1 …
Avadel Pharmaceuticals granted FDA final approval for narcolepsy drug
May 3, 2023Medical Communications FDA, FDA Approval, Neurology, avadel pharmaceuticals, narcolepsy, new drug approvals
Irish biopharmaceutical company Avadel Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has granted final approval and …
Tempus receives FDA Premarket Approval for in vitro diagnostic scan
May 3, 2023Medical Communications Diagnostics, FDA, Oncology, Tempus, in vitro
US-based artificial intelligence (AI) and precision medicine company Tempus has announced that the US Food and Drug Administration (FDA) has …
Latest content
FibroFind appoints Lee Borthwick as CEO
